Countries like the US have granted these vaccine makers immunity where they cannot be sued for any adverse effects.
Pfizer CEO has said a 3rd booster shot likely within a year of vaccination
Pfizer had a meeting with India's drugs regulator on Wednesday and the decision was made after that, the company said.
The company's Indian arm has sought emergency use authorisation (EUA) for the Pfizer/BioNTech vaccine against Covid-19 in the country from the Indian drug regulator.
Pfizer India has become the first pharma company to seek an emergency-use authorisation for its coronavirus vaccine in the country from DCGI
Pfizer has not yet applied for holding clinical trials on Indian volunteers
The U.K. had long signaled it would move fast on any promising vaccine candidate
All that happened in the markets today
Pfizer and Germany's BioNTech are in a race with companies including AstraZeneca Plc, Moderna Inc. to come up with a safe and effective vaccine against Covid-19
The eligibility of stock inclusion in the derivatives / F&O segment is based on the criteria laid down by market regulator Sebi.
Metropolis Healthcare, Bliss GVS Pharma, RPG Life Sciences, Dr. Lal PathLabs, Biocon, Albert David and FDC from the index were up more than 3 per cent.
The company had posted a net profit of Rs 131.94 crore for the corresponding period of the previous fiscal, Pfizer Ltd said in a filing to BSE.
Albert Bourla, CEO of Pfizer, discussed the time frame for the IPO at the JPMorgan Healthcare Conference in San Francisco on Tuesday
In India, PCV 13 will be introduced in a multi-dose vial format, Pfizer said
A CA by profession, Sridhar has been on Pfizer India board since May 2013